A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo.

abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

journal_title：Prostate cancer and prostatic diseases

authors： Neuhausen SL

更新日期：2000-12-01 00:00:00

abstract：BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...

journal_title：Prostate cancer and prostatic diseases

authors： Tao L,Chen J,Zhou H,Qin C,Li P,Cao Q,Li J,Ju X,Zhu C,Wang M,Zhang Z,Shao P,Yin C

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METH...

journal_title：Prostate cancer and prostatic diseases

authors： Paller CJ,Pantuck A,Carducci MA

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

journal_title：Prostate cancer and prostatic diseases

authors： Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

更新日期：2016-03-01 00:00:00

abstract：INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...

journal_title：Prostate cancer and prostatic diseases

authors： Kastner C,Armitage J,Kimble A,Rawal J,Carter PG,Venn S

更新日期：2006-01-01 00:00:00

abstract：:The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR)....

journal_title：Prostate cancer and prostatic diseases

authors： Vargas C,Martínez A,Galalae R,Demanes J,Harsolia A,Schour L,Nuernberg N,Gonzalez J

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (RT). METHODS:This was a phase 2 single-arm prospective open...

journal_title：Prostate cancer and prostatic diseases

authors： Armstrong AJ,Halabi S,Healy P,Lee WR,Koontz BF,Moul JW,Mundy K,Creel P,Wood S,Davis K,Carducci MA,Stein M,Hobbs C,Reimer B,Nguyen M,Anand M,Bratt L,Kim S,Tran PT,George DJ,Department of Defense Prostate Cancer Cli

更新日期：2016-03-01 00:00:00

abstract：:It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological...

journal_title：Prostate cancer and prostatic diseases

authors： Karavitakis M,Winkler M,Abel P,Livni N,Beckley I,Ahmed HU

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in m...

journal_title：Prostate cancer and prostatic diseases

authors： Nafie S,Mellon JK,Dormer JP,Khan MA

更新日期：2014-06-01 00:00:00

abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...

journal_title：Prostate cancer and prostatic diseases

authors： Porter CM,Shrestha E,Peiffer LB,Sfanos KS

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

journal_title：Prostate cancer and prostatic diseases

authors： Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...

journal_title：Prostate cancer and prostatic diseases

authors： Braun M,Goltz D,Shaikhibrahim Z,Vogel W,Böhm D,Scheble V,Sotlar K,Fend F,Tan SH,Dobi A,Kristiansen G,Wernert N,Perner S

更新日期：2012-06-01 00:00:00

abstract：:To describe practice patterns of primary care physicians (PCPs) for the diagnosis, treatment and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we surveyed 556 PCPs in Boston, Chicago, and Los Angeles (RR=52%). Only 62% reported ever seeing a patient like the one described in the vignette. I...

journal_title：Prostate cancer and prostatic diseases

authors： Calhoun EA,Clemens JQ,Litwin MS,Walker-Corkery E,Markossian T,Kusek JW,McNaughton-Collins M

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria i...

journal_title：Prostate cancer and prostatic diseases

authors： Russo GI,Castelli T,Favilla V,Reale G,Urzì D,Privitera S,Fragalà E,Cimino S,Morgia G

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...

journal_title：Prostate cancer and prostatic diseases

authors： Duivenvoorden WCM,Naeim M,Hopmans SN,Yousef S,Werstuck GH,Dason S,Pinthus JH

更新日期：2020-09-28 00:00:00

abstract：:Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Assikis V,Goodman M,Ward KC,Riffenburgh RH,Master V

更新日期：2007-01-01 00:00:00

abstract：:Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...

journal_title：Prostate cancer and prostatic diseases

authors： Choi HY,Lim JE,Hong JH

更新日期：2010-12-01 00:00:00

abstract：:Prostate cancer has been known to run in families for about 40 years and epidemiological studies have demonstrated an increased risk to close relatives of cases. This risk rises markedly when the closeness and number of cases in a cluster increases. There has been considerable debate about the genetic model, in partic...

journal_title：Prostate cancer and prostatic diseases

authors： Eeles RA

更新日期：1999-01-01 00:00:00

abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...

journal_title：Prostate cancer and prostatic diseases

authors： Imamoto T,Suzuki H,Yano M,Kawamura K,Kamiya N,Araki K,Komiya A,Naya Y,Shiraishi T,Ichikawa T

更新日期：2009-01-01 00:00:00

abstract：:Androgen deprivation therapy improves survival of patients with prostate cancer and leads to hypogonadal state. Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. To examine the bone loss secondary to androgen deprivation therapy, we reviewed the bo...

journal_title：Prostate cancer and prostatic diseases

authors： Yaturu S,DjeDjos S,Alferos G,Deprisco C

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...

journal_title：Prostate cancer and prostatic diseases

authors： Sargos P,Ferretti L,Gross-Goupil M,Orre M,Cornelis F,Henriques de Figueiredo B,Houédé N,Merino C,Roubaud G,Dallaudiére B,Richaud P,Fléchon A

更新日期：2014-09-01 00:00:00

abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Rossi PJ,Jani AB,Master V

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...

journal_title：Prostate cancer and prostatic diseases

authors： Den RB,Santiago-Jimenez M,Alter J,Schliekelman M,Wagner JR,Renzulli Ii JF,Lee DI,Brito CG,Monahan K,Gburek B,Kella N,Vallabhan G,Abdollah F,Trabulsi EJ,Lallas CD,Gomella LG,Woodlief TL,Haddad Z,Lam LL,Deheshi S,Wa

更新日期：2016-12-01 00:00:00

abstract：:Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...

journal_title：Prostate cancer and prostatic diseases

authors： Oades GM,Coxon J,Colston KW

更新日期：2002-01-01 00:00:00

abstract：:We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group...

journal_title：Prostate cancer and prostatic diseases

authors： Egawa S,Okusa H,Matsumoto K,Suyama K,Baba S

更新日期：2003-01-01 00:00:00

abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

journal_title：Prostate cancer and prostatic diseases

authors： Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

更新日期：2011-12-01 00:00:00

abstract：:This session included five presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new 'molecular' markers, correlation between pre- and postoperative Gleason scores and a study dealing with tra...

journal_title：Prostate cancer and prostatic diseases

authors： Sakr WA,Brawer MK,Moul JW,Donohue R,Schulman CG,Sakr D

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

journal_title：Prostate cancer and prostatic diseases

authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

journal_title：Prostate cancer and prostatic diseases

authors： McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

更新日期：2020-09-03 00:00:00

abstract：:We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...

journal_title：Prostate cancer and prostatic diseases

authors： Schroeck FR,Sun L,Freedland SJ,Jayachandran J,Robertson CN,Moul JW

更新日期：2008-01-01 00:00:00